Trials / Conditions / Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
4 registered clinical trials studyying Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type — 3 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refracto NCT06649812 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphom NCT06834373 | Mayo Clinic | Phase 2 |
| Recruiting | Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma NCT05755087 | Lapo Alinari | Phase 1 |
| Active Not Recruiting | Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have R NCT05627245 | National Cancer Institute (NCI) | Phase 1 |